Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ALNY Alnylam Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ALNY
Price (delayed)
$251.15
Market cap
$32.75B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.09
Enterprise value
$34.87B
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is
Highlights
The equity has soared by 153% YoY and by 72% from the previous quarter
ALNY's EPS is up by 21% year-on-year and by 4.1% since the previous quarter
The debt has grown by 17% YoY
Key stats
What are the main financial stats of ALNY
Market
Valuations
Earnings
Shares outstanding
130.39M
Market cap
$32.75B
Enterprise value
$34.87B
Price to earnings (P/E)
N/A
Price to book (P/B)
281.66
Price to sales (P/S)
13.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.85
Revenue
$2.35B
Gross profit
$2.02B
Operating income
-$115.37M
Net income
-$269.7M
EBIT
-$210.13M
EBITDA
-$164.54M
Free cash flow
-$75.39M
Per share
Balance sheet
Liquidity
EPS
-$2.09
EPS diluted
-$2.09
Free cash flow per share
-$0.58
Book value per share
$0.89
Revenue per share
$18.11
TBVPS
$32.49
Total assets
$4.21B
Total liabilities
$4.1B
Debt
$3.14B
Equity
$115.44M
Working capital
$2.19B
Debt to equity
27.24
Current ratio
3.04
Quick ratio
2.84
Net debt/EBITDA
-12.91
Margins
Efficiency
Dividend
EBITDA margin
-7%
Gross margin
86%
Net margin
-11.5%
Operating margin
-4.9%
Return on assets
-6.5%
Return on equity
-509.3%
Return on invested capital
-4.2%
Return on capital employed
-6.7%
Return on sales
-8.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALNY stock price
How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
-2.79%
1 week
-3.18%
1 month
3.24%
1 year
65.92%
YTD
6.73%
QTD
-6.99%
Financial performance
How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$2.35B
Gross profit
$2.02B
Operating income
-$115.37M
Net income
-$269.7M
Gross margin
86%
Net margin
-11.5%
The company's operating margin rose by 44% YoY and by 38% QoQ
Alnylam Pharmaceuticals's operating income has increased by 35% QoQ and by 34% YoY
The net margin has grown by 31% YoY and by 7% from the previous quarter
The gross profit is up by 20% YoY and by 4.9% from the previous quarter
Price vs fundamentals
How does ALNY's price correlate with its fundamentals
Growth
What is Alnylam Pharmaceuticals's growth rate over time
Valuation
What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
281.66
P/S
13.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.85
ALNY's EPS is up by 21% year-on-year and by 4.1% since the previous quarter
The equity has soared by 153% YoY and by 72% from the previous quarter
ALNY's price to sales (P/S) is 40% lower than its 5-year quarterly average of 23.2 and 5% lower than its last 4 quarters average of 14.6
The company's revenue rose by 17% YoY and by 4.4% QoQ
Efficiency
How efficient is Alnylam Pharmaceuticals business performance
The return on assets has increased by 27% year-on-year and by 4.4% since the previous quarter
ALNY's return on sales is up by 15% since the previous quarter and by 9% year-on-year
ALNY's return on invested capital is up by 14% since the previous quarter
Dividends
What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALNY.
Financial health
How did Alnylam Pharmaceuticals financials performed over time
The total assets is 2.8% more than the total liabilities
The total assets has increased by 10% YoY
Alnylam Pharmaceuticals's current ratio has increased by 9% from the previous quarter but it has decreased by 4.1% YoY
The equity has soared by 153% YoY and by 72% from the previous quarter
Alnylam Pharmaceuticals's debt to equity has decreased by 42% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.